• BioCryst to Report Fourth Quarter 2022 Financial Results on February 21

    Source: Nasdaq GlobeNewswire / 07 Feb 2023 07:00:16   America/New_York

    RESEARCH TRIANGLE PARK, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2022 financial results on Tuesday, February 21, 2023.

    BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

    The live call may be accessed by dialing 1-866-777-2509 for domestic callers and 1-412-317-5413 for international callers. A live webcast and replay of the call will be available online at the investors section of the company website at www.biocryst.com.

    About BioCryst Pharmaceuticals
    BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

    BCRXW

    Investor Contact:
    John Bluth
    +1 919 859 7910
    jbluth@biocryst.com

    Media Contact:
    Catherine Collier Kyroulis
    +1 917 886 5586
    ckyroulis@biocryst.com


    Primary Logo

Share on,